U.S. Markets closed

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.88+0.31 (+1.51%)
At close: 4:00PM EDT

20.88 0.00 (0.00%)
After hours: 4:41PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close20.57
Open20.84
Bid20.90 x 1000
Ask20.92 x 1100
Day's Range20.43 - 21.58
52 Week Range17.00 - 50.90
Volume382,422
Avg. Volume471,796
Market Cap1B
Beta (5Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-2.82
Earnings DateMay 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.75
  • Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results
    GlobeNewswire

    Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

    CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 8798968. About Constellation Pharmaceuticals Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. Contacts Kia Khaleghpour, PhDVice President, Investor Relations and CommunicationsConstellation Pharmaceuticals+1 617-844-6859kia.khaleghpour@constellationpharma.com Lauren ArnoldMedia RelationsMacDougall Biomedical Communications+1 781-235-3060larnold@macbiocom.com

  • Is CNST Stock A Buy or Sell?
    Insider Monkey

    Is CNST Stock A Buy or Sell?

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]

  • Here's Why We're Not Too Worried About Constellation Pharmaceuticals' (NASDAQ:CNST) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Constellation Pharmaceuticals' (NASDAQ:CNST) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...